
AbbVie Gains EU Approval for SKYRIZI® to Treat Ulcerative Colitis
AbbVie Announces European Approval of SKYRIZI® for Ulcerative Colitis AbbVie has received European Commission approval for SKYRIZI® (risankizumab) to treat adults with moderately to severely active ulcerative colitis (UC) who have not responded to or were intolerant of conventional or…












